Key result
Low 1,5-anhydroglucitol detects subclinical cardiac disease in T2DM with ~86% sensitivity.
Why the study?
The association between glycemic control and cardiac risk in T2DM is controversial, and whether 1,5-anhydroglucitol-measured glucose variability associates with subclinical cardiac disease was unknown.
Is diurnal blood glucose variability (measured by 1,5-AG) associated with subclinical cardiac disease in asymptomatic patients with type 2 diabetes mellitus?
Cross-Sectional (n=92)
Yes
Is diurnal blood glucose variability (measured by 1,5-AG) associated with subclinical cardiac disease in asymptomatic patients with type 2 diabetes mellitus?
Effect estimate: AUC 0.81 (95% CI 0.63-0.99)
Absolute Event Rate: 85.7% vs 75%
1,5-Anhydroglucitol (1,5-AG) may serve as a useful surrogate biomarker for identifying subclinical cardiac disease in asymptomatic patients with type 2 diabetes.
May support 1,5-AG as biomarker for subclinical cardiac disease in T2DM; hypothesis-generating and requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Shehab-Eldin et al. (2020) conducted a cross-sectional in Type 2 Diabetes Mellitus and Subclinical Cardiac Disease (n=92). 1,5-Anhydroglucitol (1,5-AG) measurement vs. Healthy subjects was evaluated on Diagnostic accuracy of 1,5-AG < 7.51 ng/ml for subclinical cardiac disease (AUC 0.81, 95% CI 0.63-0.99). A 1,5-anhydroglucitol level of less than 7.51 ng/ml identified subclinical cardiac disease in patients with type 2 diabetes mellitus with 85.7% sensitivity, 75% specificity, and an AUC of 0.81.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: